Navigation Links
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Date:2/23/2009

met-inc.com) is a biopharmaceutical company with offices in Bethesda, MD and Munich, Germany. The Company is focused on developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company's novel antibody technology is based on its proprietary BiTE(R) antibody platform, representing a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, LLC, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a traditional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. Micromet licensed a fourth clinical stage antibody, MT293, to TRACON Pharmaceuticals, Inc. MT293 is being developed in a phase 1 clinical trial for the treatment of patients with cancer. The Company's preclinical programs include MT203 being developed in collaboration with Nycomed. MT203 is a traditional human antibody neutralizing the activity of gr
'/>"/>
SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
2. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
3. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
4. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
5. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
6. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
7. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
8. Micromet to Present at Two Upcoming Investor Conferences
9. Micromet to Present at the Susquehanna Financial Groups SIGnificant Investment Options Conference on March 4, 2008
10. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
11. Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... Boston, MA (PRWEB) August 21, 2014 ... collaboration company, has been recognized as one of ... 500 | 5000 magazine for the 2nd consecutive ... on its 33rd annual Inc. 500|5000, an exclusive ... list represents the most comprehensive look at the ...
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3
... Repligen,Corporation (Nasdaq: RGEN ) announced today that ... BMY ) in its lawsuit alleging,infringement of U.S. ... sale of Orencia(R) for the treatment of rheumatoid,arthritis. The ... of $5,000,000 and to pay royalties on the U.S. ...
... April 8 The Board of Molecular Vision ... acquisition,of Molecular Vision have now ceased. Acrongenomics has ... agreed. Given this, the Board of,Molecular Vision believes ... served,by bringing these discussions to a conclusion. Acrongenomics ...
... based strategic market research firm expands its presence in Europe ... and deepens its methodological expertise., ... the appointment of Penny Mesure as a Director based in ... support and,facilitate the continuing expansion of the company,s European and ...
Cached Biology Technology:Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit 2Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit 3Observant LLC Appoints Two New Directors to the Senior Management Team 2
(Date:8/21/2014)... National University (ANU) team has successfully replicated one of ... biological systems powered by sunlight which could manufacture hydrogen ... is sunlight. It is an exciting prospect to use ... safely," said Dr Kastoori Hingorani, from the ARC Centre ... School of Biology. , Hydrogen offers potential as a ...
(Date:8/20/2014)... HOUSTON, Aug. 20, 2014 George E. Fox, a John ... University of Houston (UH), was named a fellow in the ... (ISSOL). , Fox is one of four members ... Spain chosen as fellows in 2014. Fellows are elected ... With more than 500 members from more than 20 countries, ...
(Date:8/20/2014)... of Tennessee, Knoxville, research finds life can persist in ... was part of a team that examined waters and ... ice sheet and found the extreme environment supports microbial ... Jill Mikucki and her colleagues has implications for life ... the solar system. The findings are published in the ...
Breaking Biology News(10 mins):Water and sunlight the formula for sustainable fuel 2UH professor named fellow by International Astrobiology Society 2University of Tennessee research uncovers subglacial life beneath Antarctic ice sheet 2
... at the University of Leicester have released satellite images of ... which are currently sweeping across central and western Russia. ... University,s Earth Observation Science group have analysed and released still ... satellite image is available as both a true colour image ...
... soap can help build electrodes for cheaper lithium ion ... of Nano Letters . The one-step method will ... lithium ion-metal oxide batteries currently on the market. ... electrode materials," said material scientist Daiwon Choi of the ...
... Montreal, August 12, 2010 Dr. Jean-Philippe ... unit at the Institut de recherches cliniques de ... for modulating vascular permeability: the nitrosylation of beta-catenin ... have a possible impact on the treatment of ...
Cached Biology News:Fires around Moscow: A satellite perspective 2Wax, soap clean up obstacles to better batteries 2Wax, soap clean up obstacles to better batteries 3Wax, soap clean up obstacles to better batteries 4An IRCM researcher pinpoints the cellular mechanism responsible for modulating the permeability of blood vessels 2
Ready-to-use solution....
Applications: ISH...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
Biology Products: